Kristina Burow Sells 3,053 Shares of Scholar Rock (NASDAQ:SRRK) Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Kristina Burow sold 3,053 shares of the business’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $53.74, for a total value of $164,068.22. Following the transaction, the director owned 114,657 shares in the company, valued at approximately $6,161,667.18. This represents a 2.59% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Scholar Rock Trading Up 2.2%

SRRK opened at $56.56 on Wednesday. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $57.80. The company has a debt-to-equity ratio of 0.71, a current ratio of 8.64 and a quick ratio of 8.64. The business has a 50 day simple moving average of $48.79 and a two-hundred day simple moving average of $46.75. The firm has a market capitalization of $6.78 billion, a price-to-earnings ratio of -15.75 and a beta of 0.67.

Scholar Rock (NASDAQ:SRRK) last posted its earnings results on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.01). During the same quarter in the previous year, the firm earned ($0.67) earnings per share. Analysts predict that Scholar Rock Holding Corporation will post -3.23 EPS for the current year.

Hedge Funds Weigh In On Scholar Rock

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. IFP Advisors Inc boosted its holdings in shares of Scholar Rock by 294.1% during the 4th quarter. IFP Advisors Inc now owns 603 shares of the company’s stock valued at $27,000 after buying an additional 450 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new position in shares of Scholar Rock in the 4th quarter worth about $30,000. Summit Securities Group LLC purchased a new position in Scholar Rock during the 4th quarter valued at about $31,000. Ramirez Asset Management Inc. purchased a new position in Scholar Rock during the 3rd quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC boosted its stake in Scholar Rock by 151.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 872 shares of the company’s stock worth $38,000 after acquiring an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 91.08% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on SRRK. Barclays upped their price objective on shares of Scholar Rock from $53.00 to $55.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. JPMorgan Chase & Co. lifted their target price on shares of Scholar Rock from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Monday, March 16th. Canaccord Genuity Group started coverage on shares of Scholar Rock in a research note on Monday, April 20th. They issued a “buy” rating and a $62.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Scholar Rock in a report on Tuesday, April 21st. Finally, Wedbush lifted their price objective on Scholar Rock from $56.00 to $58.00 and gave the company an “outperform” rating in a research report on Wednesday, April 1st. Four investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $56.00.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).